Following last year, Hanmi Science surpassed the 1st trillion won mark in cumulative revenue for the third quarter of this year as well. This is a result driven by growth in the pharmaceutical distribution sector and healthcare business.
On the 27th, Hanmi Science provisionally disclosed that it recorded consolidated Q3 revenue of 362.9 billion won, operating profit of 19.2 billion won, and net income of 15.6 billion won for this year.
Revenue increased by 5.9% compared to the same period last year, while operating profit and net income decreased by 51.3% and 51.1%, respectively, compared to the same period last year. This is due to the base effect from Hanmi Pharm’s technology exports. Cumulative Q3 revenue was 1.0844 trillion won, a 7.1% increase over the same period last year. Cumulative operating profit was 111.9 billion won, and net income was 101.5 billion won, representing increases of 10.8% and 19.9%, respectively, compared to the same period last year.
The company explained that these results were driven by balanced growth across group affiliates, including the pharmaceutical distribution sector (Online Farm) and its in-house healthcare business. Online Farm recorded revenue of 308.1 billion won, a 7.3% increase from the same period last year, thanks to the expansion of its domestic distribution business centered on prescription drugs (ETC).
Hanmi Science is also expanding the competitiveness of its in-house businesses in various ways. In the medical device sector, strong performance of key products such as “Gadix” and “ActiClot,” combined with expanded revenue for “Liquid Band XL” and the unification of medical device codes and securing an overseas export base for “Surge Guard,” has further strengthened business competitiveness.
Meanwhile, consumer health businesses including soy milk, care food, health functional foods, and cosmetics are also progressing smoothly. Strong sales of new products, such as “Retinoate Cream” from the pharmacy-exclusive dermocosmetic brand “Pro-Calm (PRO-CALM),” contributed to performance. The expansion of B2C (business-to-consumer) channel sales for “Complete Soy Milk” and the entry into new home shopping and pharmacy channels for the all-in-one nutritional food brand “Care Me” supported results.
The company is cultivating future growth drivers by broadening its portfolio into the cosmetics market through the newly launched health functional food brand “NPLE (엔플)” and dermocosmetic brand “ADESII (아데시)” this year.
A Hanmi Science official stated, “Q3 results are the outcome of robust distribution competitiveness and in-house business growth generating full-fledged synergy.” The official added, “Going forward, we will focus all our efforts on organically expanding our business portfolio from medical devices to consumer health, wellness, and beauty to strengthen competitiveness, maximizing synergy among affiliates to leap as a global healthcare leader.”
in THEBIO
